Revvity (NYSE:RVTY) PT Raised to $126.00 at KeyCorp

Revvity (NYSE:RVTYFree Report) had its target price raised by KeyCorp from $110.00 to $126.00 in a research note issued to investors on Friday, Benzinga reports. KeyCorp currently has an overweight rating on the stock.

A number of other research analysts have also recently commented on RVTY. The Goldman Sachs Group reduced their price objective on Revvity from $120.00 to $105.00 and set a buy rating on the stock in a research note on Tuesday, October 31st. Barclays boosted their price objective on Revvity from $92.00 to $105.00 and gave the stock an equal weight rating in a research note on Thursday, January 25th. Wolfe Research began coverage on Revvity in a research note on Wednesday, December 13th. They issued a peer perform rating on the stock. Raymond James cut their price target on Revvity from $135.00 to $106.00 and set an outperform rating on the stock in a research note on Tuesday, October 31st. Finally, Evercore ISI upgraded Revvity from an in-line rating to an outperform rating and boosted their price target for the stock from $88.00 to $125.00 in a research note on Thursday, January 4th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $118.91.

Check Out Our Latest Report on Revvity

Revvity Price Performance

Shares of Revvity stock opened at $103.90 on Friday. The business’s fifty day moving average price is $103.65 and its 200 day moving average price is $105.96. The stock has a market capitalization of $12.82 billion, a P/E ratio of 18.89, a PEG ratio of 2.79 and a beta of 1.11. Revvity has a twelve month low of $79.50 and a twelve month high of $144.50. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTYGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The company reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. The company had revenue of $695.90 million for the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. As a group, research analysts anticipate that Revvity will post 4.59 earnings per share for the current year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity’s payout ratio is currently 5.09%.

Institutional Investors Weigh In On Revvity

Several large investors have recently modified their holdings of RVTY. Parkside Financial Bank & Trust purchased a new stake in shares of Revvity in the fourth quarter valued at $25,000. Gladius Capital Management LP lifted its holdings in shares of Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after purchasing an additional 106 shares in the last quarter. CENTRAL TRUST Co purchased a new stake in shares of Revvity in the fourth quarter valued at $27,000. ORG Partners LLC purchased a new stake in shares of Revvity during the fourth quarter worth $32,000. Finally, JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Revvity during the fourth quarter worth $33,000. 82.63% of the stock is owned by institutional investors.

Revvity Company Profile

(Get Free Report)

Revvity, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Recommended Stories

Analyst Recommendations for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.